Recent advances in opioid prescription for chronic non-cancer pain

Postgraduate Medical Journal

Volumn 88, Issue 1036, 2012, Pages 66-72

  Snidvongs, Saowarat ^a   Mehta, Vivek ^a  

^a BARTS HEALTH NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; CODEINE; DIHYDROCODEINE; FENTANYL; LAXATIVE; METHADONE; MORPHINE; MORPHINE SULFATE PLUS NALTREXONE; NALOXONE; NICOTINIC ACID PLUS OXYCODONE; OPIATE; OXYCODONE; TAPENTADOL; TARGINACT; TRAMADOL; UNCLASSIFIED DRUG;

ARTICLE; CANCER PAIN; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; DRUG ABUSE; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DEPENDENCE; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; FLUSHING; HIP PAIN; HUMAN; KNEE PAIN; MEDICAL SPECIALIST; NAUSEA; NEUROPATHIC PAIN; PAIN; PATIENT CARE; PATIENT REFERRAL; PRACTICE GUIDELINE; PRESCRIPTION; SIDE EFFECT; UNITED KINGDOM; UNITED STATES;

ANALGESICS, OPIOID; CHRONIC PAIN; DISEASE MANAGEMENT; DRUG TOLERANCE; HUMANS; PATIENT COMPLIANCE; PHENOLS; QUALITY OF LIFE; SUBSTANCE-RELATED DISORDERS;

EID: 84856013097     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2010.112045     Document Type: Article

References (49)

1. Merskey H, Bogduk N. Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms. 2nd edn. Seattle: IASP Press, 1994: 209-14.
2. Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006; 10: 287-333.
3. Kalso E, Edwards JE, Moore RA, et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain 2004; 112: 372-80.
4. Quigley C. The role of opioids in cancer pain. BMJ 2005; 331: 825-9.
5. Davies AN, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 2009; 13: 331-8.
6. Stein C, Reinecke H, Sorgatz H. Opioid use in chronic noncancer pain: guidelines revisited. Curr Opin Anaesthesiol 2010; 23: 598-601.
7. The British Pain Society. Opioids for persistent pain: good practice. A consensus statement prepared on behalf of the British Pain Society, the Faculty of Pain Medicine of the Royal College of Anaesthetists, the Royal College of General Practitioners and the Faculty of Addictions of the Royal College of Psychiatrists. London, UK: The British Pain Society, 2010.
8. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10: 113-30.
9. Trescot AM, Helm S, Hansen H, et al. Opioids in the management of chronic noncancer pain: an update of the American Society of Interventional Pain Physicians' (ASIPP) guidelines. Pain Physician 2008; 11(2 Suppl): S5-62.
10. Chapman CR, Lipschitz DL, Angst MS, et al. Opioid pharmacotherapy for chronic non-cancer pain in the United States: a research guideline for developing an evidence-base. J Pain 2010; 11: 807-29.
11. Campbell CI, Weisner C, Leresche L, et al. Age and gender trends in long-term opioid analgesic use for noncancer pain. Am J Public Health 2010; 100: 2541-7.
12. Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev 2010; (1): CD006605.
13. Rauck RL. What is the case for prescribing long-acting opioids over short-acting opioids for patients with chronic pain? A critical review. Pain Pract 2009; 9: 468-79.
14. Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Cochrane Database Syst Rev 2006; (3): CD006146.
15. Pergolizzi J, Böger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008; 8: 287-313.
16. American Academy of Pain Medicine, the American Pain Society and the American Society of Addiction Medicine. Definitions related to the use of opioids for the treatment of pain. WJM 2001; 100: 28-9.
17. Vissers KC, Besse K, Hans G, et al. Opioid rotation in the management of chronic pain: where is the evidence? Pain Pract 2010; 10: 85-93.
18. Joint Formulary Committee. British National Formulary. 59th edn. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2010.
19. King Pharmaceuticals. Avinza®. http://www.avinza.com (accessed 14 Mar 2011).
20. Rosenthal M, Moore P, Groves E, et al. Sleep improves when patients with chronic OA pain are managed with morning dosing of once a day extended-release morphine sulfate (AVINZA): findings from a pilot study. J Opioid Manag 2007; 3: 145-54.
21. Delemos BP, Xiang J, Benson C, et al. Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and/or hip: a double-blind, randomized, dose-ranging trial. Am J Ther 2011; 18: 216-26.
22. Rosenberg MT. The role of tramadol ER in the treatment of chronic pain. Int J Clin Pract 2009; 63: 1531-43.
23. Margetts L, Sawyer R. Transdermal drug delivery: principles and opioid therapy. Contin Educ Anaesth Crit Care 2007; 7: 171-6.
24. Grünenthal GmbH. Press Release. Centrally Acting Analgesics: Experts Propose Tapentadol as Representative of New Drug Class MOR-NRI, 6 September, 2010. http://www.grunenthal.com/grt-web/Grunenthal_Group/Press_Centre/News/2010/115200146.jsp?listItemID=144300359&listID=128900117&customDisplayTemplatePath=/grt-web/WEB-INF/templates/includes/presslist/press_news.jsp (accessed 18 Jun 2011).
25. Candiotti KA, Gitlin MC. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution? Curr Med Res Opin 2010: 26: 1677-84.
26. Guay DR. Is tapentadol an advance on tramadol? Consult Pharm 2009; 24: 833-40.
27. Wade WE, Spruill WJ. Tapentadol hydrochloride: a centrally acting oral analgesia. Clin Ther 2009; 31: 2804-18.
28. Afilalo M, Etropolski MS, Kuperwasser B, et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig 2010; 30: 489-505.
29. Wild JE, Grond S, Kuperwasser B, et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract 2010; 10: 416-27.
30. Napp Pharmaceuticals. Targinact®. Summary of Product Characteristics. http://www.medicines.org.uk/EMC/medicine/22908/SPC/Targinact+5+mg+2.5+mg%2c+10+mg+5+mg%2c+20+mg+10+mg+and+40+mg+20+mg+prolonged-release+tablets(accessed 14 Mar 2011).
31. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003; 63: 649-71.
32. Simpson K, Leyendecker P, Hopp M, et al. Fixed-ratio combination oxycodone/ naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin 2008; 24: 3503-12.
33. Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioidinduced constipation. Eur J Pain 2009; 13: 56-64.
34. Vondrackova D, Leyendecker P, Meissner W, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 2008; 9: 1144-54.
35. Raffa RB, Pergolizzi JV Jr. Opioid formulations designed to resist/deter abuse. Drugs 2010; 70: 1657-75.
36. Durect Corporation. Remoxy®. http://www.durect.com/wt/durect/page_name/remoxy (accessed 14 Mar 2011).
37. King Pharmaceuticals. Embeda®. http://www.embeda.com (accessed 14 Mar 2011).
38. Acura Pharmaceuticals. Acurox® with Niacin Tablets. http://acurapharm.com/products/acurox-tablets (accessed 14 Mar 2011).
39. Incline Therapeutics. IONSYS® (fentanyl iotophoretic transdermal system. http://inclinethera.com (accessed 14 Mar 2011).
40. Medicines and Healthcare products Regulatory Authority class 1 medicines recall alert. http://www.mhra.gov.uk/Publications/Safetywarnings/DrugAlerts/CON025960 (accessed 14 Mar 2011).
41. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med 2010; 152: 85-92.
42. Fitzgibbon DR, Rathmell JP, Michna E, et al. Malpractice claims associated with medication management for chronic pain. Anesthesiology 2010; 112: 948-56.
43. Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med 2010; 363: 1981-5.
44. Gilson AM. State medical board members' attitudes about the legality of chronic prescribing to patients with noncancer pain: the influence of knowledge and beliefs about pain management, addiction and opioid prescribing. J Pain Symptom Manage 2010; 40: 599-612.
45. Shah S, Diwan S. Methadone: does stigma play a role as a barrier to treatment of chronic pain? Pain Physician 2010; 13: 289-93.
46. Lewis ET, Combs A, Trafton JA. Reasons for under-use of prescribed opioid medications by patients in pain. Pain Med 2010; 11: 861-71.
47. Rhodin A, Stridsberg M, Gordh T. Opioid endocrinopathy: a clinical problem in patients with chronic pain and long-term oral opioid treatment. Clin J Pain 2010; 26: 374-80.
48. Rittner HL, Roewer N, Brack A. The clinical (ir)relevance of opioid-induced immune suppression. Curr Opin Anaesthesiol 2010; 23: 588-92.
49. Chou R, Ballantyne JC, Fanciullo GJ, et al. Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain 2009; 10: 147-59.